Cargando…
miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
BACKGROUND: MicroRNA-221(miR-221) is frequently dysregulated in cancer. The purpose of this study was to explore whether miR-221 can be used as a potential diagnostic marker or therapeutic target for hepatocellular carcinoma (HCC). METHODS: In this study, we investigated whether miR-221 expression w...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907790/ https://www.ncbi.nlm.nih.gov/pubmed/29713162 http://dx.doi.org/10.2147/IJN.S157805 |
_version_ | 1783315608665849856 |
---|---|
author | Li, Feng Wang, Feiran Zhu, Changlai Wei, Qun Zhang, Tianyi Zhou, You Lang |
author_facet | Li, Feng Wang, Feiran Zhu, Changlai Wei, Qun Zhang, Tianyi Zhou, You Lang |
author_sort | Li, Feng |
collection | PubMed |
description | BACKGROUND: MicroRNA-221(miR-221) is frequently dysregulated in cancer. The purpose of this study was to explore whether miR-221 can be used as a potential diagnostic marker or therapeutic target for hepatocellular carcinoma (HCC). METHODS: In this study, we investigated whether miR-221 expression was associated with clini-copathological characteristics and prognosis in HCC patients, and we developed a nanoparticle-based miRNA delivery system and detected its therapeutic efficacy in vitro and in vivo. RESULTS: We found that miR-221 was upregulated in HCC tissues, cell lines and blood of HCC patients. Upregulated miR-221 was associated with clinical TNM stage and tumor capsular infiltration, and showed poor prognosis, suggesting that its suppression could serve as an effective approach for hepatocellular carcinoma therapy. Treatment of HCC cells with nanoparticle/miR-221 inhibitor complexes suppressed their growth, colony formation ability, migration and invasion. In vivo, the growth of the tumors treated by the nanoparticle/miR-221 inhibitor complexes were significantly less than those treated by the nanoparticle/miRNA scramble complexes. In addition, circulating miR-221 may act as a potential tumor biomarker for early diagnosis of HCC, and combined serum miR-221 and AFP detection gave a better performance than individual detection in early diagnosis of HCC. CONCLUSION: These findings suggest that a nanoparticle-based miRNA delivery system could potentially serve as a safe and effective treatment and miR-221 could also be a potential diagnostic marker for HCC. |
format | Online Article Text |
id | pubmed-5907790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59077902018-04-30 miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker Li, Feng Wang, Feiran Zhu, Changlai Wei, Qun Zhang, Tianyi Zhou, You Lang Int J Nanomedicine Original Research BACKGROUND: MicroRNA-221(miR-221) is frequently dysregulated in cancer. The purpose of this study was to explore whether miR-221 can be used as a potential diagnostic marker or therapeutic target for hepatocellular carcinoma (HCC). METHODS: In this study, we investigated whether miR-221 expression was associated with clini-copathological characteristics and prognosis in HCC patients, and we developed a nanoparticle-based miRNA delivery system and detected its therapeutic efficacy in vitro and in vivo. RESULTS: We found that miR-221 was upregulated in HCC tissues, cell lines and blood of HCC patients. Upregulated miR-221 was associated with clinical TNM stage and tumor capsular infiltration, and showed poor prognosis, suggesting that its suppression could serve as an effective approach for hepatocellular carcinoma therapy. Treatment of HCC cells with nanoparticle/miR-221 inhibitor complexes suppressed their growth, colony formation ability, migration and invasion. In vivo, the growth of the tumors treated by the nanoparticle/miR-221 inhibitor complexes were significantly less than those treated by the nanoparticle/miRNA scramble complexes. In addition, circulating miR-221 may act as a potential tumor biomarker for early diagnosis of HCC, and combined serum miR-221 and AFP detection gave a better performance than individual detection in early diagnosis of HCC. CONCLUSION: These findings suggest that a nanoparticle-based miRNA delivery system could potentially serve as a safe and effective treatment and miR-221 could also be a potential diagnostic marker for HCC. Dove Medical Press 2018-04-13 /pmc/articles/PMC5907790/ /pubmed/29713162 http://dx.doi.org/10.2147/IJN.S157805 Text en © 2018 Li et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Li, Feng Wang, Feiran Zhu, Changlai Wei, Qun Zhang, Tianyi Zhou, You Lang miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title | miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title_full | miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title_fullStr | miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title_full_unstemmed | miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title_short | miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
title_sort | mir-221 suppression through nanoparticle-based mirna delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907790/ https://www.ncbi.nlm.nih.gov/pubmed/29713162 http://dx.doi.org/10.2147/IJN.S157805 |
work_keys_str_mv | AT lifeng mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT wangfeiran mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhuchanglai mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT weiqun mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhangtianyi mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhouyoulang mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker |